Skip to main content

Advertisement

Log in

Gaucher disease: perspectives on a prototype lysosomal disease

  • Published:
Cellular and Molecular Life Sciences CMLS Aims and scope Submit manuscript

Abstract.

Gaucher disease is an autosomal recessive trait and the most common lysosomal storage disease. The pathogenesis evolves from the diminished activity of the lysosomal hydrolase, acid β-glucosidase and the resultant accumulation of glucosylceramide within lysosomes. The pathogenic mechanisms are poorly understood. During the past 2 decades, progress has been made in understanding the biochemical basis and molecular biology of the disease, but more fundamental knowledge is required to relate these advances to the cell and whole body phenotypes. Despite this lack of understanding, enzyme replacement therapy has proved a successful and effective management for Gaucher disease. However, basic details of this therapeutic efficacy require elucidation. Here, we review the current state of the molecular pathogenesis and provide our perspective of some major issues for continued advances in this prototype lysosomal storage disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received 25 October 2001; received after revision 3 December 2001; accepted 3 December 2001

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, H., Grabowski, G. Gaucher disease: perspectives on a prototype lysosomal disease. CMLS, Cell. Mol. Life Sci. 59, 694–707 (2002). https://doi.org/10.1007/s00018-002-8458-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-002-8458-y

Navigation